eflapegrastim
Rolvedon (eflapegrastim) is a long-acting G-CSF analogue that stimulates the bone marrow to make neutrophils. Given after myelosuppressive chemotherapy for non-myeloid cancers, it shortens the period of low white cells and reduces febrile neutropenia.
This page is based on FDA prescribing information and the DailyMed label for eflapegrastim, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Chemotherapy is like a storm that flattens the bone marrow's neutrophil nursery. G-CSF is the fertilizer that regrows it. Eflapegrastim is a slow-release version of that fertilizer, attached to a long-lasting carrier, so one dose after each cycle keeps the nursery rebuilding for days instead of hours.
In simple terms
Many chemotherapy drugs lower the number of neutrophils, the white blood cells that fight bacteria, leaving patients at risk of serious infection. Eflapegrastim mimics G-CSF, the natural hormone that tells the bone marrow to produce neutrophils. Its structure keeps it in the body longer than ordinary G-CSF, so a single injection after chemotherapy helps neutrophil counts recover sooner and reduces episodes of fever with low white cells.
In depth
Eflapegrastim is a recombinant fusion of a modified G-CSF with a human Fc fragment linked via a polyethylene glycol-containing scaffold, extending half-life relative to filgrastim. It binds and activates the G-CSF receptor on myeloid progenitors, stimulating proliferation, differentiation and functional activation of neutrophils. Administered once per chemotherapy cycle, it reduces the duration and severity of chemotherapy-induced neutropenia and the incidence of febrile neutropenia.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How G-CSF analogues regrow the neutrophil nursery
- Eflapegrastim mimics G-CSF, the natural hormone that tells the bone marrow to produce neutrophils.
- Its structure keeps it in the body longer than ordinary G-CSF.
- It binds and activates the G-CSF receptor on myeloid progenitors, stimulating proliferation, differentiation and functional activation of neutrophils.
- A single injection after chemotherapy helps neutrophil counts recover sooner and reduces episodes of fever with low white cells.
Target: Granulocyte colony-stimulating factor (G-CSF) receptor
A receptor on neutrophil precursor cells that, when stimulated, drives their production and maturation in the bone marrow; chemotherapy suppresses this system, and stimulation restores it.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
Official sources
The statements on this page trace back to these records.
- DailyMed: Rolvedon (eflapegrastim) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: eflapegrastim prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: eflapegrastim
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.